Efficacy and safety of a hyaluronic acid-containing cream in the treatment of chronic, venous, or mixed-origin leg ulcers: a prospective, multicenter, randomized, controlled trial
| ISRCTN | ISRCTN15487707 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN15487707 |
| Secondary identifying numbers | 16FPL- iacr09 |
- Submission date
- 23/11/2020
- Registration date
- 23/11/2020
- Last edited
- 02/12/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
A cream containing 0.2% hyaluronic acid as an active ingredient has been developed and marketed for over 20 years for the topical treatment of non-infected, exuding or superinfected wounds, including leg ulcers. Ialuset® cream creates a moist environment around the wound that promotes healing. It is applied on a daily basis in addition to standard of care. The aim of this study is to confirm the effectiveness and safety of Ialuset cream compared with a neutral comparator cream.
Who can participate?
Patients aged 18 and over with a venous leg ulcer
What does the study involve?
Participants are randomly allocated to have ialuset® cream or a neutral comparator cream applied once daily for a maximum of 20 weeks or until complete ulcer healing, whichever occurs first. There are a total of eight visits for each participant, consisting of screening/inclusion (Visit 0), randomization and first treatment (Visit 1), Weeks 4, 8, 12, 16, and 20 of treatment (Visits 2–6), and a final evaluation (follow-up) visit (visit 7) at day 162 (week 23) or 3 weeks after complete healing if it occurs before week 20. The healing of the target ulcer is assessed and recorded at each study visit. The target ulcer is evaluated by the Investigator and documented by standardized digital photography.
What are the possible benefits and risks of participating?
The patients may benefit from effective treatment of their leg ulcer. The study does not involve any major risks as the treatment is very well known.
Where is the study run from?
IBSA Institut Biochimique (Switzerland)
When is the study starting and how long is it expected to run for?
February 2017 to July 2020
Who is funding the study?
IBSA Institut Biochimique SA (Switzerland)
Who is the main contact?
Carol Caverzasio
carol.caverzasio@ibsa.ch
Contact information
Scientific
Via Pian Scairolo 49
Pazzallo
6912
Switzerland
 ORCID ID |
0000-0002-2697-4271 |
|---|---|
| Phone | +41 (0)583601696 |
| carol.caverzasio@ibsa.ch |
Study information
| Study design | Confirmatory multicentre multinational prospective parallel-group randomized double-blind clinical investigation |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | No participant information sheet available |
| Scientific title | A confirmatory multicentre, multinational, prospective, parallel-group, randomized, double-blind clinical investigation of the performance and safety of Ialuset® cream versus neutral comparator cream in the treatment of chronic, venous or mixed origin leg ulcer |
| Study objectives | Efficiency (performance) of Ialuset® cream is superior to a neutral comparator in the treatment of chronic leg ulcers of venous or mixed origin. This hypothesis will be judged by comparing the proportion of subjects that achieved complete target ulcer healing (defined as 100% re-epithelialisation of the wound area) after 20 weeks of treatment and confirmed after 3 weeks from the treatment completion. |
| Ethics approval(s) | 1. Approved 05/04/2017, Bioethics committee at the medical district in Lodz, (ul, Czerwona 3, 93-005 Lodz, Poland; +48 (0)426 831 744; email: not provided), ref: K.B.-9/17 2. Approved 26/06/2017, Personal protection committee Ile-de-France IV, Pitié-Salpetriere Hospital (47 boulevard de l'hôpital, 75651 Paris Cedex 13, France; +33 (0)1 42 16 16 83; email: not provided), ref: 25-17 ID-RCB: 2017-A00892-51 |
| Health condition(s) or problem(s) studied | Treatment of chronic, venous or mixed origin leg ulcer |
| Intervention | Eligible particpants are randomly allocated to Ialuset® cream or a neutral comparator in a ratio of 1:1 using a centralized randomisation system. Target ulcer size (target ulcer size ≤20 cm² or >20 cm²) is applied as a stratification factor. Treatment assignment is determined by the unique randomisation number allocated to the participant by the central randomisation system. The randomisation number corresponds to an IMD labelled with an identical number. Ialuset® cream or neutral comparator cream is applied once daily for maximum 20 weeks (active treatment period) or until complete ulcer healing, whichever occurred first. Ialuset® cream or neutral comparator cream is applied directly on the ulcer identified as target ulcer for the investigation. The wound is cleansed with a physiological solution and debrided when necessary prior to cream application. The cream application is followed by a sterile gauze dressing application and appropriate compression bandaging. |
| Intervention type | Device |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Ialuset® cream |
| Primary outcome measure | The proportion (%) of subjects with completely healed target ulcer (defined as 100% reepithelialisation of the wound area based on standardised photographs of the target ulcer), as observed at Study Visit 6, or at any earliest study visit and further confirmed at a follow-up visit 3 weeks post last treatment, centrally assessed on standardized pictures |
| Secondary outcome measures | 1. Percentage of patients with complete ulcer healing at 20 weeks and confirmed 3 weeks later, assessed by PI 2. Percentage of patients with complete ulcer healing at 4, 8, 12, 16, 20 and 23 weeks, centrally assessed 3. Target ulcer residual area (% relative) to baseline, centrally assessed at 4, 8, 12, 16, 20 and 23 weeks 4. Condition of the peri-ulcerous skin assessed by PI at 4, 8, 12, 16, 20 and 23 weeks 5. Total amount (doses) of analgesics consumed collected by the PI at 4, 8, 12, 16, 20 and 23 weeks 6. Percentage of subjects with infection of the target ulcer recorded by the PI after the start of IMD application 7. Compliance to the treatment assessed as the % IMD daily application counted from the returned IMD 8. Time to complete healing as centrally assessed calculated using percentage of complete healing over time 9. Pain measured using VAS score at 4, 8, 12, 16, 20 and 23 weeks 10. Safety outcomes measured using AEs, SAEs described by MeDRA system organ classes, frequency of AEs/SAEs and percentage of patients experiencing AEs/SAEs at 4, 8, 12, 16, 20 and 23 weeks |
| Overall study start date | 24/02/2017 |
| Completion date | 18/07/2020 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 168 |
| Total final enrolment | 170 |
| Key inclusion criteria | 1. Adult male and female (aged ≥18 years) 2. Subject diagnosed with a leg ulcer >2 months and <4 years duration 3. Subject diagnosed with one or several leg ulcers of mere venous (varicose or post-thrombotic) origin, or of mixed venous and arterial origin with predominance of venous aetiology 4. Presence of an ulcer that was intended to be treated with a surface area ≥5 cm² and ≤40 cm² 5. Subject having undergone an arterial-venous Doppler examination within 6 months prior to inclusion, showing a superficial or profound reflux in the venous system, and/or a well-documented past history of deep venous thrombosis of the lower limbs, and/or clinical evidence of post-thrombotic syndrome with chronic oedema and lipodermatosclerosis Ankle/brachial Doppler systolic pressure index ≥0.8 and ≤1.2 within 6 months prior to inclusion 6. Patient whose leg ulcer compression system was adapted and worn during the study 7. Subject having an albuminemia ≥25 g/l (measured ≤2 weeks prior to inclusion) 8. Female subjects of childbearing potential having a negative urine pregnancy test result at screening and at the randomisation visit, and practising two reliable methods of contraception throughout the study 9. Subject having a satisfactorily general condition and a life expectancy longer than the duration of the study, according to the Investigator 10. Having signed a written informed consent to participate in the study, according to GCP 11. For France: subjects covered by a health insurance system/policy |
| Key exclusion criteria | 1. Subject with an ulcer of non-venous origin (e.g., phagedenic pyodermatitis, pyoderma gangrenosum, neoplastic or infectious origin) or related to a general cause (e.g., haematological cause). 2. Presence of necrotic tissue ≥50% of the target ulcer surface area 3. Subject with clinical evidence of a significant arterial insufficiency (claudication, pain of decubitus ulcers), and/or Ankle-Brachial Pressure Index (ABPI) <0.8 or >1.2 4. Subject with any type of diabetes mellitus, as per medical records (i.e. glycated haemoglobin – HbA1c <6.5%) or investigator judgment. (Note: HbA1c <6.5% was a typographical error and the investigators were told to interpret that as HbA1c >6.5%. This error was present in CIP v1.0, 24Feb2017, CRF v3.0, 11Aug2017) 5. Subject suffering from severe hepatic disorders (with serum activity of ALT/AST ≥2.5 UNL) or severe renal disorders (creatinine clearance <30 ml/min) identified within 3 months prior to inclusion 6. Subject with a clinical suspicion of wound infection (e.g., erysipelas, phlegmon) based on the presence of at least one of the following symptoms: peri-ulcerous inflammation, odorous and purulent flow, adenopathy, lymphangitis, fever, unexpected healing interruption, or abscess. 7. Ulcer with exposed tendon or bone 8. Ulcer due to local or extended malignancy 9. An episode of acute deep vein thrombosis (DVT) within 3 months prior to inclusion 10. Subject under treatment with drugs known to adversely affect the healing process: i.e., systemic corticosteroids, cytostatic drugs, immunosuppressive agents |
| Date of first enrolment | 13/06/2017 |
| Date of final enrolment | 17/04/2019 |
Locations
Countries of recruitment
- France
- Poland
Study participating centres
Dijon
21000
France
Lodz
94-238
Poland
Sponsor information
Industry
Via Pian Scairolo 49
Pazzallo
6912
Switzerland
| Phone | +41 (0)583601696 |
|---|---|
| carol.caverzasio@ibsa.ch | |
| Website | http://www.ibsa.it/home.html |
"ROR" |
https://ror.org/051tj3a26 |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 18/07/2021 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | 1. For the time being, neither the clinical study protocol nor any other study document is expected to be made available 2. Planned publication in a peer-reviewed journal |
| IPD sharing plan | The data sharing plans for the current study are unknown and will be made available at a later date |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 01/11/2021 | 14/03/2022 | Yes | No |
Editorial Notes
02/12/2022: Contact and sponsor details updated.
28/03/2022: Phase was changed from Phase IV to Not Applicable.
14/03/2022: Publication reference added.
23/11/2020: Trial's existence confirmed by bioethics committee at the medical district in Lodz and personal protection committee Ile-de-France IV, Pitié-Salpetriere Hospital.
